EUCTR2009-015939-33-GB进行中（未招募）1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Adult women or men, age = 55 to = 95 years at randomization
- •Fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to repair by internal fixation
- •Intertrochanteric fractures eligible for this study must have at least two displaced fragments
- •Internal fixation of the fracture with devices approved by local regulatory agency, performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures
- •Intertrochanteric fracture: sliding hip screw or IM nail
- •Femoral neck fracture: sliding hip screw or at least three cancellous screws
- •Pre- and postoperative care performed as defined in Appendix I
- •Subject or subject’s legally acceptable representative has provided informed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •Conditions that may affect the ability to perform functional or clinical
- •assessments required by the protocol, such as:
- •Severe symptomatic osteoarthritis of the lower extremity
- •Inability to independently rise from armchair or walk 200 meters before hip
- •fracture (use of unilateral assistive device or rolling walker is acceptable)
- •Cognitive deficit, as defined by Mini-Mental Status Examination score < 22 at
- •time of randomization
- •Symptomatic neurological conditions such as Parkinson’s disease or persistent
- •gross motor or sensory deficits such as hemiparesis or hemiplegia
- •Presence of concomitant injuries such as rib fractures, wrist fractures, or acute
- •symptomatic vertebral fractures which severely impair the ability to rise from a
- •Associated extremity injuries including ipsilateral or contralateral fractures of the
- •foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation,
- •that may delay weight-bearing beyond one week after surgery
- •Use of bone grafts or bone substitutes at the time of fracture fixation
- •Head-injury, as defined by Glasgow Coma Scale <13 prior to randomization
- •Major polytrauma or significant axial trauma, with Injury Severity Score > 16
- •Pathological fracture or history of metabolic or bone disease (except
- •osteoporosis) that may interfere with the interpretation of the results, such as Paget’s disease, rheumatoid
- •arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing’s disease,
- •hyperprolactinemia
- •History of symptomatic spinal stenosis that has not been surgically corrected. If surgically corrected, the subject must be asymptomatic to be eligible for the study
- •History of facial nerve paralysis
- •Malignancy (except fully resected cutaneous basal cell or squamous cell
- •carcinoma, cervical carcinoma in situ) within the last 5 years
- •Severe asthma or severe chronic obstructive pulmonary disease or recent exacerbation
- •Myocardial infarction or unstable angina pectoris within the last 12 months
- •Current alcohol dependence
- •History of solid organ or bone marrow transplants
- •Per subject report, chart review or local laboratory result, evidence of currently abnormal values for the following:
- •Elevated transaminases (a) Serum aspartate aminotransferase = 2.0 x
- •upper limits of normal; (b) Serum alanine aminotransferase = 2.0 x upper
- •limits of normal
- •Significantly impaired renal function as determined by a derived creatinine
- •clearance of = 30 mL/min using the Modification of Diet in Renal Disease
- •equation (Levey et al, 1999). The estimated glomerular filtration rate is
- •calculated as follows: estimated glomerular filtrat
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - AMG 785 20062017Acceleration of fracture healingMedDRA version: 12.1Level: LLTClassification code 10043827Term: Tibia fractureEUCTR2008-008392-34-ITAmgen Inc.400
进行中（未招募）
1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT) - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT)Acceleration of fracture healingMedDRA version: 13.1 Level: PT Classification code 10043827 Term: Tibia fracture System Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-GBAmgen Inc400
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo. - RADIANTEUCTR2005-001747-29-ESOSI Pharmaceuticals, Inc.945
进行中（未招募）
不适用
Study of AMG785 in hip fractureAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10016454Term: Femur fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2009-015939-33-BEAmgen Inc330
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine theEfficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Proximal Femur, Status Post Fixation with a Sliding Hip Screw or Intramedullary NailEUCTR2009-015939-33-SEAmgen Inc330